WT1 Immunoprofiling and Comparison of Malignant Mullerian Mixed Tumors of The Female Genital Tract

Abstract

A malignant Mullerian mixed tumor (MMMT) is a biphasic homologous or heterologous malignancy of the female genital tract. WT1 (Wilms tumor 1) is both a tumor suppressor gene and oncogene overexpressed in the nuclei of some gynecologic carcinomas. Expression in MMMT is incompletely described. Whole sections from 16 MMMTs were stained with WT1 (N terminus) using a standard immunoperoxidase technique. There were 7 heterologous and 9 homologous tumors and 10 were endometrial, 5 were ovarian, and 1 was of peritoneal origin. The tissue and cell staining pattern and score (intensity by amount) were evaluated and correlated with the tumor subtype and anatomic location. Among the 16 tumors, 81.3% showed mostly stromal and cytoplasmic staining and a score of 3 or 6. Staining was positive in 80% of the endometrial and ovarian tumors and the 1 peritoneal tumor and in all heterologous and 66.7% of the homologous tumors. The immunoprofile correlated with tumor subtype but not with anatomic location. Stromal and epithelial staining was more frequent (83.3%) in homologous tumors and differed significantly (P=0.009) from the heterologous types where stromal staining prevailed (85.7%). MMMT is another genital tract malignancy which can over express WT1 and the immunoprofile may assist in tumor subtyping.

Eight cases of malignant mixed müllerian tumor (carcinosarcoma) of the uterus: Findings in surepath™ cervical cytology

“…Although immunostains are generally not needed in the histologic diagnosis of MMMT/CSs, they may be useful in the demonstration of unusual mesenchymal elements (desmin, myoD1, myoglobin, and sarcomeric actin for rhabdomyosarcomatous elements, S‐100 for cartilaginous elements). Immunopositivity for p16, p53, and WT1 is seen in the majority of MMMT in both epithelial and mesenchymal components but it is typically negative in benign cells present in Pap tests.…”

Diagnostic and Prognostic Role of WT1 Immunohistochemical Expression in Uterine Carcinoma: A Systematic Review and Meta-Analysis across All Endometrial Carcinoma Histotypes

“…Therefore, to better clarify this issue, we conducted a systematic review and meta-analysis, including all published papers on the WT1 immunohistochemical expression across all histotypes of endometrial carcinoma. The present paper included a total of 35 eligible studies with 52 datasets and 1616 patients for qualitative analysis [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ].…”

A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies

“…Here, we report the results of a phase I study of WT2725. The WT2725 dosing emulsion was administered as a monotherapy to patients with advanced malignancies (glioblastoma, AML, NSCLC, and ovarian cancer) known to overexpress the WT1 protein in the majority of patients 3 , 4 , 41 . The study was conducted to determine dose levels for use in future clinical studies, and to evaluate safety, tolerability, and clinical and immunological responses.…”